Scotts Valley, CA, United States of America

Michael J Delmage

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Celtrix Pharmaceuticals, Inc.. Active years: 2000.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael J Delmage: Innovator in Ophthalmic Treatments

Introduction

Michael J Delmage is a notable inventor based in Scotts Valley, California. He has made significant contributions to the field of ophthalmology through his innovative methods for treating ophthalmic disorders. His work focuses on addressing conditions associated with insulin-like growth factors.

Latest Patents

Delmage holds a patent for a method aimed at treating ophthalmic disorders with insulin-like growth factor binding protein (IGFBP). This method specifically targets disorders linked to an excess of IGF-I or IGF-II. The preferred form of IGFBP used in this treatment is IGFBP-3. This patent showcases his commitment to advancing medical treatments and improving patient outcomes.

Career Highlights

Delmage is associated with Celtrix Pharmaceuticals, Inc., where he applies his expertise in developing innovative therapeutic solutions. His work at the company reflects his dedication to enhancing healthcare through scientific research and development.

Collaborations

Delmage collaborates with Andreas Sommer, contributing to the advancement of ophthalmic treatments. Their partnership exemplifies the importance of teamwork in the field of medical innovation.

Conclusion

Michael J Delmage's contributions to ophthalmic treatment methods highlight his role as a key innovator in the medical field. His patent and work at Celtrix Pharmaceuticals, Inc. demonstrate his commitment to improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…